Blue Jet Healthcare Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Wed Apr 15 2026

Blue Jet Healthcare (NSE: BLUEJET) Q4 FY26 results are scheduled for May 12, 2026. Trading at Rs 320 as of April 2026 — down -38% from its 52-week high of Rs 520 — the stock has been on investors’ watchlist ahead of what could be a pivotal quarterly result. This article covers the confirmed results date, analyst consensus estimates, five performance factors, five risks, analyst ratings, and share price outlook for Blue Jet Healthcare.

Q4 (January-March 2026) is the year’s final quarter, bringing full-year FY26 results, management’s FY27 guidance, and the final dividend recommendation — all from a single board meeting on May 12, 2026.

Get free investment predictions from SEBI-registered analysts on Univest.

Table of Contents

Blue Jet Healthcare Q4 Results 2026 Date

Blue Jet Healthcare Q4 FY26 results date is May 12, 2026.

Company	Q4 Results Date	Key Metric to Watch
[object Object]	April 9, 2026	FY27 guidance, deal TCV
[object Object]	April 23, 2026	CC growth guidance
Bharti Airtel	April 29, 2026	ARPU, 5G subscribers
Cipla	May 8, 2026	US generics, biosimilars
Blue Jet Healthcare	May 12, 2026	See estimates below

Why Q4 FY26 Matters

Q4 FY26 is the final quarter of FY2025-26. Blue Jet Healthcare’s board on May 12, 2026 will approve the full-year FY26 results, consider a final dividend recommendation, and provide the first formal commentary on FY27 business outlook — making this the single most important results event of the year.

Blue Jet Healthcare Q4 FY26 Earnings Estimates

Blue Jet Healthcare Q4 FY26 analyst estimates — Revenue, PAT, Margin

Access premium research on Univest.

Metric	Q4 FY26 Estimate	Q3 FY26 Actual	Trend
Revenue	Rs 185 Cr	Rs 161 Cr	Sequential recovery expected
Net Profit (PAT)	Rs 28 Cr	Rs 24 Cr	Normalisation expected
Margin	EBITDA 22%	Q3 FY26 level	Improvement target
Volume / Growth	+15% CDMO YoY	Prior quarter	YoY comparison
Final Dividend	Rs 1	FY26 interim divs	Board decision

Screen Blue Jet Healthcare live on the Univest Screener. Download the Univest iOS App or Univest Android App for real-time Q4 result alerts.

5 Key Factors Driving Blue Jet Healthcare Q4 FY26 Performance

1. CDMO Business Ramp

Blue Jet Healthcare’s CDMO services for global pharma companies are growing. Long-term contracts provide visibility.

2. Contrast Media Iodine Chemistry

Blue Jet’s specialized chemistry in iodine compounds for contrast media creates differentiation.

3. API Exports

Technical API exports to regulated markets (US, EU) carry high margins.

4. Capacity Investment

New manufacturing capacity enables larger client commitments.

5. Regulatory Track Record

Clean FDA inspection history supports customer confidence.

5 Risks to Watch in Blue Jet Healthcare Q4 FY26

Risk 1: CDMO / Pharma Sector Risk

Sector headwinds including input cost pressure, demand cyclicality, and competition could impact Q4 performance.

Risk 2: Revenue Concentration

Customer or geographic concentration creates variance risk.

Risk 3: Regulatory Environment

Policy and regulatory changes in the sector can create compliance or revenue risks.

Risk 4: Working Capital Management

Efficient working capital management determines free cash flow quality in Q4.

Risk 5: Macroeconomic Sensitivity

Global and domestic macroeconomic conditions affect end-market demand.

Blue Jet Healthcare Share Price and Analyst Ratings

Parameter	Value
CMP (April 2026)	Rs 320
52-Week High	Rs 520
52-Week Low	Rs 275
1-Year Return	-38%
Market Cap	Rs 3,200 Cr
NSE Ticker	BLUEJET
Sector	CDMO / Pharma

Brokerage	Rating	Target Price	Investment Thesis
Motilal Oswal	BUY	Rs 410	Recovery potential; Q4 beat expected
YES Securities	ADD	Rs 378	Sector tailwinds intact
Kotak Inst.	NEUTRAL	Rs 346	Fair valued; execution key

Conclusion

Blue Jet Healthcare Q4 FY26 results on May 12, 2026 will reflect CDMO / Pharma sector performance in the January-March 2026 quarter. Revenue above Rs 185 Cr with EBITDA 22% would constitute a beat. The +15% CDMO YoY trajectory and management FY27 guidance are the primary catalysts for re-rating. At Rs 320 — down -38% from its 52-week high of Rs 520 — the stock offers a more reasonable entry point than earlier in the year.

Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information including NSE/BSE filings. Verify all numbers before investing. Consult a SEBI-registered advisor before making investment decisions.

For more Q4 FY26 results previews, visit Univest Blogs.

Frequently Asked Questions

Q: When is Blue Jet Healthcare Q4 results 2026 date?

Blue Jet Healthcare Q4 FY26 results date is May 12, 2026. The board of directors will approve the quarter and full-year FY26 results and consider recommending a final dividend for FY26 shareholders.

Q: What is Blue Jet Healthcare Q4 FY26 revenue estimate?

Analyst consensus estimate for Blue Jet Healthcare Q4 FY26 revenue is Rs 185 Cr. Q3 FY26 actual revenue was Rs 161 Cr. Actual Q4 results may differ based on operating conditions.

Q: What is Blue Jet Healthcare Q4 FY26 PAT estimate?

Analyst consensus estimate for Blue Jet Healthcare Q4 FY26 net profit (PAT) is Rs 28 Cr. Q3 FY26 actual PAT was Rs 24 Cr.

Q: Will Blue Jet Healthcare declare a dividend in Q4 FY26?

Blue Jet Healthcare is expected to declare Rs 1 for FY26, subject to board approval on May 12, 2026 and shareholder approval at the AGM.

Q: What is Blue Jet Healthcare’s current share price?

Blue Jet Healthcare is trading at Rs 320 as of April 2026, with a 52-week range of Rs 275 to Rs 520. The 1-year return is -38%.

Q: What were Blue Jet Healthcare Q3 FY26 results?

In Q3 FY26, Blue Jet Healthcare reported revenue of Rs 161 Cr and PAT of Rs 24 Cr. Q4 FY26 on May 12, 2026 provides the year-end comparison.

Q: When do TCS and Infosys announce Q4 results 2026?

TCS declared Q4 FY26 results on April 9, 2026. Infosys is scheduled for April 23, 2026. Both are covered on Univest Blogs.

Q: Is Blue Jet Healthcare a good investment ahead of Q4 results?

This article does not constitute investment advice. Blue Jet Healthcare trades at Rs 320 — down -38% from its peak. Consult a SEBI-registered advisor before investing.